MHRA Drug Safety Update

October 2024

GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse

Healthcare professionals are reminded to inform patients about the common and serious side effects associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs).

Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on reporting suspected adverse incidents and safety concerns to the MHRA’s Yellow Card scheme

We ask healthcare professionals to support new guidance for users of diabetes management equipment, their families, care givers and representatives.

Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation

A safety review has been conducted by the MHRA following a Yellow Card report concerning a patient who was taking bromocriptine. The review concluded that blood pressure monitoring of patients prescribed with this drug is essential especially during the first days of treatment.

Letters and medicine recalls sent to healthcare professionals in September 2024

A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.

It's easy to report

Report a suspected adverse drug reaction online
or download the Yellow Card app

REPORT ONLINE

Drug Safety Update is a monthly newsletter from the Medicines and Healthcare products Regulatory Agency (MHRA) and its independent advisor the Commission on Human Medicines.

NICE has accredited the process used by the MHRA to produce Drug Safety Update guidance. More information on accreditation can be viewed on the NICE website.